Clinical and Economic Management of Uterine Fibroids: The Point of View of a Decision Makers Board

La gestione clinica ed economica del fibroma uterino: il punto di vista di un Decision Makers Board

Authors

  • Costantino Di Carlo Dipartimento Universitario di Scienze Ostetrico-Ginecologiche, Urologiche e Medicina della Riproduzione, Università di Napoli Federico II, Napoli - Italy
  • Antonio Maiorana U.O.C. di Ginecologia e Ostetricia, A.R.N.A.S. Ospedale Civico, Palermo - Italy
  • Ignazia Poidomani Dipartimento del Farmaco, Azienda Sanitaria Provinciale di Ragusa, Segretario Regionale SIFO - Italy
  • Roberto Ravasio Health Publishing & Services Srl, Milano - Italy
  • Adriano Vercellone Dipartimento del Farmaco ASL Napoli 3 SUD, Segretario Regionale SIFO - Italy

DOI:

https://doi.org/10.33393/grhta.2016.365

Keywords:

Cost-minimization analysis, Surgery, Therapeutic Diagnostic Path, Ulipristal acetate, Uterine fibroids

Abstract

Uterine fibroids can have a significant economic impact on the National Healthcare Service and on Society overall (absenteeism and disability). Women with uterine fibroids have higher use of medical services and procedures. The management and treatment of uterine fibroids thence imposes a burden on the existing National Healthcare Service and it is important to understand the economic implications between treatment options and key cost drivers. Our analysis is limited to describe the disease management and pharmacological costs of uterine fibroids. Our focus is on clinical data, therapeutic options, treatment costs and unmet needs (therapeutic diagnostic path). Knowledge of these aspects can be a useful tool for the clinician in order to select the most effective treatment in clinical practice, tailored on patients' characteristics.

Most read articles by the same author(s)

<< < 1 2 3 4 5